The Italian gene therapy company Genenta Science SRL has raised €13.2 million in a new financing round to progress novel treatments for multiple myeloma and glioblastoma that deliver immunomodulatory molecules into the tumour environment. The company has received regulatory approval to start Phase 1/2 clinical trials in both cancer indications.
The new financing brings total capital raised by the company up to €30.2 million since its founding in 2014 as a spin-out from the San Raffaele Hospital in Milan.